Kaizen Bioconsulting - R&D Strategy Consulting




Drug Discovery

  • Significant experience in the design, set-up, and leadership of drug and vaccine development projects
  • Experienced in assessing the feasibility of technologies, projects, and proposals, and the development of R&D strategy


  • Led programme of research to identify Candida albicans antigens
  • Successfully applied for renewals of EU grant-funding for albicans consortium
  • Established external collaborations for production of monoclonal antibodies, set-up of in vivo models, and bioinformatic analyses
  • Designed in-vivo models of Klebsiella pneumoniae infection for evaluation of Klebsiella antigens
  • Devised criteria for selection of antigens for Shigella flexneri, Enterotoxigenic Escherichia coli (ETEC), Enteroaggregativecoli (EAEC), and other gram-negative pathogens
  • Supervised technicians and students carrying out studies in Molecular Microbiology
  • Conducted PhD and postdoctoral studies on pathogenesis of Neisseria meningitidis infection

Project Leadership

  • Led Candida, Shigella and ETEC projects
  • Prepared numerous scientific literature reviews, scientific reports, presentations, and patents
  • Identified and assessed potential collaborators and partners
  • Set-up collaborations and agreements working closely with legal and IP departments
  • Prepared reports on status of project goals and milestones and presented recommendations to senior management to facilitate decision-making and development of R&D strategy

Business Development

  • Identified, researched, and recommended experts in field of Pseudomonas aeruginosa, anti-infectives, and clinical trials
  • Conducted feasibility and market assessments of wide range of nosocomial and emerging pathogens as potential targets for application of antigen identification platform
  • Led and managed team of twelve staff to successfully deliver ‘UK Dementia Research: Addressing the Global Challenge’ conference for Prime Minister’s Dementia Challenge to showcase the UK’s dementia research to industry, communicating with numerous senior clinical academics, companies, and organizations

Consortium Management

  • Coordinated all activities within four work packages (project management, clinical trials, training and capacity building, and networking & data management) for Malaria Vectored Vaccines Consortium (MVVC) aimed at integrating capacity building and networking into design and conduct of Phase I and Phase II clinical trials of viral vectored candidate malaria vaccines in East and West African children and infants.

MVVC partners: European Vaccine Initiative, University of Oxford (sponsor), Okairos srl., Vienna School of Clinical Research (VSCR), Centre National de Recherche et Formation sur le Paludisme, Burkina Faso (CNRFP), Kenya Medical Research Institute (KEMRI), MRC Gambia, and Universite Cheikh Anta Diop, Senegal (UCAD)

  • Managed CANVAC consortium, an industry-academic partnership between Intercell, University of Vienna, and GATC Biotech, and four external groups aimed at developing vaccines and monocolonal antibody therapies for treatment of Candida infections

Medical Communications

  • Experienced in researching disease areas, carrying out literature reviews, identifying experts in niche areas, and writing summaries, recommendations, and reports



Graduate Diploma in Law (2009)
BPP Law School, London

PhD Molecular Genetics of Neisseria meningitidis (2004)
University of Oxford
MSc Molecular Genetics (1996)
University of Leicester
BSc (Hons) Biochemistry (1995)
University of Kent at Canterbury

Please see my LinkedIn profile for further details at uk.linkedin.com/in/drsharmilabakshi/